The influence of bone marrow- and synovium-derived mesenchymal stromal cells from osteoarthritis patients on regulatory T cells in co-culture

Clinical and Experimental Immunology

Volumn 173, Issue 3, 2013, Pages 454-462

  Hagmann, S ^a   Gotterbarm, T ^a   Muller T ^a   Baesig, A M ^a   Gantz, S ^a   Dreher, T ^a   Kammerer P W ^b   Frank, S ^a   Zeifang, F ^a   Moradi, B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Co culture; IL 6; Inflammation; Mesenchymal stromal cells; Osteoarthritis; Regulatory T cells

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALPHA1 INTEGRIN; CD146 ANTIGEN; CD4 ANTIGEN; ENDOGLIN; HERMES ANTIGEN; HLA ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; MICROSOMAL AMINOPEPTIDASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; THY 1 ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HIP OSTEOARTHRITIS; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MAGNETIC SEPARATION; MALE; MESENCHYMAL STROMA CELL; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPERNATANT; SYNOVIUM;

CO-CULTURE; IL-6; INFLAMMATION; MESENCHYMAL STROMAL CELLS; OSTEOARTHRITIS; REGULATORY T CELLS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE MARROW CELLS; COCULTURE TECHNIQUES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OSTEOARTHRITIS; SYNOVIAL MEMBRANE; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84881488374     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12122     Document Type: Article

References (50)

1. Alvarez-Soria MA, Largo R, Santillana J etal. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006; 65:998-1005.
2. Benito-Miguel M, Garcia-Carmona Y, Balsa A etal. A dual action of rheumatoid arthritis synovial fibroblast IL-15 expression on the equilibrium between CD4+CD25+ regulatory T cells and CD4+CD25- responder T cells. J Immunol 2009; 183:8268-8279.
3. Young L, Katrib A, Cuello C etal. Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study. Arthritis Rheum 2001; 44:343-350.
4. Bullough P. Pathology of osteoarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. Edinburgh: Mosby, 2003:1835-1845.
5. Myers SL, Brandt KD, Ehlich JW etal. Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol 1990; 17:1662-1669.
6. Revell PA, Mayston V, Lalor P etal. The synovial membrane in osteoarthritis: a histological study including the characterisation of the cellular infiltrate present in inflammatory osteoarthritis using monoclonal antibodies. Ann Rheum Dis 1988; 47:300-307.
7. Smith MD, Triantafillou S, Parker A etal. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24:365-371.
8. Guo X, Zheng Q, Yang S etal. Repair of full-thickness articular cartilage defects by cultured mesenchymal stem cells transfected with the transforming growth factor beta1 gene. Biomed Mater 2006; 1:206-215.
9. Jiang Y, Jahagirdar BN, Reinhardt RL etal. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418:41-49.
10. Lyons FG, Al-Munajjed AA, Kieran SM etal. The healing of bony defects by cell-free collagen-based scaffolds compared to stem cell-seeded tissue engineered constructs. Biomaterials 2010; 31:9232-9243.
11. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262:509-525.
12. Zhao S, Wehner R, Bornhauser M etal. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev 2010; 19:607-614.
13. Zappia E, Casazza S, Pedemonte E etal. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106:1755-1761.
14. Ortiz LA, Dutreil M, Fattman C etal. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007; 104:11002-11007.
15. Togel F, Hu Z, Weiss K etal. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289:F31-42.
16. Guo J, Lin GS, Bao CY etal. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation 2007; 30:97-104.
17. Le Blanc K, Rasmusson I, Sundberg B etal. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-1441.
18. Jones E, Churchman SM, English A etal. Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level. Ann Rheum Dis 2010; 69:450-457.
19. Augello A, Tasso R, Negrini SM etal. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007; 56:1175-1186.
20. Batten P, Sarathchandra P, Antoniw JW etal. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng 2006; 12:2263-2273.
21. Krampera M, Glennie S, Dyson J etal. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722-3729.
22. Bartholomew A, Sturgeon C, Siatskas M etal. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-48.
23. Di Nicola M, Carlo-Stella C, Magni M etal. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838-3843.
24. Di Ianni M, Del Papa B, De Ioanni M etal. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36:309-318.
25. Maccario R, Podesta M, Moretta A etal. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90:516-525.
26. Prevosto C, Zancolli M, Canevali P etal. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007; 92:881-888.
27. Behrens F, Himsel A, Rehart S etal. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis 2007; 66:1151-1156.
28. Hagmann S, Moradi B, Müller T etal. Interaction of human mesenchymal stromal cells and regulatory T-cells in osteoarthritis [Abstract]. Osteoarthritis Cartilage 2011; 19:S30-31.
29. Moradi B, Rosshirt N, Hagmann S etal. Osteoarthritis progression is accompanied by inflammatory CD4+ T-cell polarisation [Abstract]. Osteoarthritis Cartilage 2012; 20:S232-233.
30. National Library of Medicine (NLM) at the National Institutes of Health (NIH). ClinicalTrials.gov., homepage. Available at: http://clinicaltrials.gov (accessed 10 December 2012).
31. Davatchi F, Abdollahi BS, Mohyeddin M etal. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2010; 14:211-215.
32. Dexheimer V, Mueller S, Braatz F etal. Reduced reactivation from dormancy but maintained lineage choice of human mesenchymal stem cells with donor age. PLoS ONE 2011; 6:e22980.
33. Dominici M, Le Blanc K, Mueller I etal. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-317.
34. Ryan JM, Barry FP, Murphy JM etal. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2:8.
35. Engela AU, Baan CC, Peeters AM etal. Interaction between adipose-tissue derived mesenchymal stem cells and regulatory T cells. Cell Transplant 2013; 22:41-54.
36. Marek N, Bieniaszewska M, Krzystyniak A etal. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant 2011; 20:1747-1758.
37. Seddiki N, Santner-Nanan B, Martinson J etal. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-1700.
38. Murphy JM, Dixon K, Beck S etal. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002; 46:704-713.
39. Dudics V, Kunstar A, Kovacs J etal. Chondrogenic potential of mesenchymal stem cells from patients with rheumatoid arthritis and osteoarthritis: measurements in a microculture system. Cells Tissues Organs 2009; 189:307-316.
40. Scharstuhl A, Schewe B, Benz K etal. Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology. Stem Cells 2007; 25:3244-3251.
41. Arufe MC, De la Fuente A, Fuentes-Boquete I etal. Differentiation of synovial CD-105(+) human mesenchymal stem cells into chondrocyte-like cells through spheroid formation. J Cell Biochem 2009; 108:145-155.
42. Ju YJ, Muneta T, Yoshimura H etal. Synovial mesenchymal stem cells accelerate early remodeling of tendon-bone healing. Cell Tissue Res 2008; 332:469-478.
43. Sakaguchi Y, Sekiya I, Yagishita K etal. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum 2005; 52:2521-2529.
44. Djouad F, Bony C, Haupl T etal. Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther 2005; 7:R1304-1315.
45. Eikawa S, Ohue Y, Kitaoka K etal. Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 2010; 185:6734-6740.
46. Zeng C, Shi X, Zhang B etal. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl) 2012; 90:175-186.
47. Svobodova E, Krulova M, Zajicova A etal. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012; 21:901-910.
48. Fujimoto M, Nakano M, Terabe F etal. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 2011; 186:32-40.
49. Herrath J, Muller M, Amoudruz P etal. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur J Immunol 2011; 41:2279-2290.
50. Aroen A, Loken S, Heir S etal. Articular cartilage lesions in 993 consecutive knee arthroscopies. Am J Sports Med 2004; 32:211-215.